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Abstract (269 words; 300 maximum)
Background: Gefapixant is a P2X3 receptor antagonist in development for treatment of 
refractory (RCC) and unexplained chronic cough (UCC). 
Methods: We conducted a 12-week, Phase 2b, randomized, double-blind, placebo-controlled 
study in patients with RCC or UCC (>1 year) with no radiographic chest abnormality and ≥40 
mm on the Cough Severity Visual Analog Scale [VAS].  Patients were randomized to receive 
placebo or gefapixant (7·5 mg BID, 20 mg BID, or 50 mg BID).  The primary efficacy endpoint 
was placebo-adjusted change from baseline in Awake Cough Frequency (coughs/hour) after 12 
weeks of treatment. Adverse events (AE) were monitored throughout the study.
Findings: 253 patients were randomized to placebo (n=63), gefapixant 7·5 mg (n=64), 20 mg 
(n=63), or 50 mg (n=63). Mean (SD) age was 60 (10·0) years and 76% of patients were women. 
At 12 weeks, Geometric Mean Awake Cough Frequency was 18·2, 14·5, 12·0, 11·3 coughs/hr 
with placebo and gefapixant 7·5 mg, 20 mg, and 50 mg, respectively; % change vs. placebo 
(95% CI) was -37% (-53·3,-14·9) with gefapixant 50 mg (p=0·003), -22·2% (-42,4·3) with 20 mg 
(p=0·093), and -22·0% (-41·8,4·6) with 7·5 mg (p=0·097). Dysgeusia was the most common AE, 
occurring in 5%, 10%, 33%, and 48% of placebo and gefapixant 7·5-mg, 20-mg, and 50-mg 
patients, respectively.
Interpretation: Targeting P2X3 with gefapixant at a dose of 50 mg BID significantly reduces 
cough frequency in patients with RCC and UCC after 12 weeks of treatment compared with 
placebo. Gefapixant was generally well tolerated with dysgeusia being the most frequent AE.
Funding: This study was funded by Afferent Pharmaceuticals, which has been acquired by 
Merck & Co., Inc., Kenilworth, NJ, USA.
Clinical Trials Registry: NCT02612610
Research in Context
Evidence before this study 
Literature search: Pubmed search, Oct 2015 terms: P2X3, Chronic Cough
Chronic cough affects 4-10% of the general population, a proportion of whom have cough that 
does not resolve upon treatment of underlying conditions or for whom underlying conditions 
cannot be found.  Hyper-excitability of neuronal pathways mediating cough may be a therapeutic 
target for patients with refractory or unexplained condition. A previous study of gefapixant, a 
P2X3 receptor antagonist at a supratherapeutic dose of 600 mg demonstrated significant 
reduction in cough frequency in patients with refractory chronic cough.
Added value of this study 
We report the results from the largest trial to date in chronic cough subjects. This trial evaluated 
lower doses of gefapixant within a therapeutic dose range and over a longer (12 week)treatment 
period. 
Implications of all the available evidence 
These results confirm the therapeutic potential of targeting P2X3 receptors for clinically 
meaningful reduction of chronic cough. The evidence from this trial supports further 
development of gefapixant. 
Future Research
Phase 3 studies evaluating gefapixant are ongoing and will confirm efficacy and tolerability of 
this novel mechanism.
Introduction 
Epidemiological studies indicate chronic cough (i.e., cough lasting >8 weeks), affects 4-10% of 
adults. Yet, currently, there are no effective licensed therapies for this problem.1,2 In never-
smokers, individuals reporting chronic cough are likely to be older, female, have abdominal 
obesity, occupational exposure to dust/fumes, or diagnosed with conditions such as  asthma, 
gastroesophageal reflux disease, upper airway cough syndrome, and bronchiectasis.1 
Nonetheless, among patients diagnosed with these conditions, the vast majority did not complain 
of chronic coughing, suggesting a distinct pathophysiological process responsible for the 
symptom trait of chronic cough.
Whilst some patients with chronic cough improve with treatment of these associated conditions, 
it is increasingly recognized that many do not; such patients are often classified as having 
refractory chronic cough (RCC). A minority of chronic cough patients have no evidence of any 
underlying condition and may be considered to have unexplained chronic cough (UCC). Cough 
Hypersensitivity Syndrome (CHS) has been described as a diagnosis that may be applicable to 
RCC and UCC and has been hypothesized to be due to disordered sensory neural function.3 
While treatment options remain limited, hyper-excitability of neuronal pathways mediating 
cough may be a therapeutic target and, indeed, there is some evidence that RCC patients may 
respond to therapies that modulate neuronal function (e.g. morphine, gabapentin, amitriptyline) 
and behavioural interventions.4-6 
P2X3 receptors are ATP-gated ion channels found predominantly on peripheral sensory nerves 
and known to be expressed by fibres innervating the airways.7 A small proof-of-concept study in 
patients with RCC demonstrated that two weeks treatment with high-dose (i.e., 600 mg BID) 
gefapixant (MK-7264; previously known as AF-219), a P2X3 receptor antagonist, reduced 
objective cough frequency by an unprecedented 75% over placebo.8 Subsequent studies 
suggested that maximum efficacy was still retained at doses as low as 50 mg BID with an 
improved tolerability profile9,10 (manuscript in preparation). The aim of the current randomized 
controlled trial was to evaluate the effectiveness of three doses of gefapixant (7·5 mg, 20 mg, and 
50 mg BID) compared with placebo after 12 weeks of treatment in reducing frequency of 
coughing during waking hours in RCC/UCC patients. Cough frequency over 24 hours and 
patient reports of the severity and impact of their chronic cough were also assessed.
Methods 
Participants
Patients with RCC or UCC for ≥ one year according to ACCP/BTS guidelines11,12 and with no 
significant abnormality contributing to cough on chest radiology within the last 5 years were enrolled. 
Women or men between 18- 80 years of age and with ≥40 mm on the Cough Severity Visual Analogue 
Scale (VAS) at the Screening Visit were eligible.
Patients were excluded if they were current smokers, had only quit smoking within 6 months of the study, 
had an FEV1/FVC <60%, opioid use within 1 week of the study, or had either initiated treatment with an 
ACE inhibitor or had an upper or lower respiratory tract infection within 4 weeks of the study. A complete 
list of the inclusion and exclusion criteria is provided in the Supplement.
Study Conduct and Design
This 12-week, Phase 2b, randomized, double-blind, placebo-controlled, parallel-group study (Sponsor 
Protocol 012; Clinical Trials Registry NCT02612610) was approved by Investigational Review Boards/
Ethics Review Committees and conducted in accordance with principles of Good Clinical Practice in 44 
centres in the United Kingdom and the United States. Patients provided informed consent before 
enrolment.
Patients were screened during a 2-week period. On Day 0, patients underwent baseline assessments and 
received the first dose of study drug the next morning (Day 1), administered in the clinic.  Subsequent 
Treatment Visits were scheduled for Days 28, 42, 56, 70, 84, and 85, and Follow-up Visits on Days 98 
and 99.  
Randomisation and masking 
Patients were randomly assigned in a 1:1:1:1 ratio to gefapixant 7·5 mg BID, 20 mg BID, or 50 mg BID, 
or a matching placebo. The randomization was stratified by country and was performed via a centralized 
Interactive Voice or Web Response System (IVRS/IWRS). The randomization schedule was computer 
generated using a permuted block algorithm and randomly allocated subjects to randomization numbers. 
A 2-stage randomization was used. Subjects were first randomized to 1 of the 3 dose groups using a 
balanced 1:1:1 (Group1: MK-7264 7.5 mg or matched placebo; Group 2: MK-7264 20 mg or matched 
placebo; Group 3: MK-7264 50 mg or matched placebo) randomization. After being randomized to their 
dose group, subjects were randomized using an unbalanced 3:1 (MK-7264 to placebo) randomization. 
The randomization was stratified by country.
This study employed a double-masking design where subjects and all personnel involved with the 
conduct and the interpretation of the study, including the Investigators, investigational site personnel, 
contract research organization (CRO), home health nurses, readers at Vitalojak, and Sponsor staff, were 
blinded to the treatment codes. Randomisation data were kept strictly confidential, filed securely by an 
appropriate group at the Sponsor (Merck & Co., Inc., Kenilworth, NJ, USA) or CRO, and accessible only 
to authorized persons until the time of unmasking. Unmasking was available 24 hours per day/7 days per 
week and was performed by IVRS/IWRS. Only in the case of an emergency, when knowledge of the 
investigational product was essential for the welfare of a subject, an Investigator may have unmasked a 
subject’s treatment assignment.
Efficacy Evaluation
The primary efficacy endpoint was change from baseline in awake objective cough frequency after 12 
weeks (Day 84) of treatment; objective cough frequency was captured with 24-hour sound recordings at 
Baseline and on Days 28, 56, 84, and 98 using an acoustic recording device (VitaloJAK, Vitalograph Ltd, 
Buckinghamshire UK). Change from baseline in 24-hour objective cough frequency at 4 weeks (day 28), 
8 weeks (day 56), and 12 weeks (day 84), change from baseline in awake objective cough frequency after 
4 weeks (Day 28), 8 weeks (day 56), and follow-up at 14 weeks (Day 98) were key secondary endpoints. 
Patient-reported outcomes were evaluated including the key secondary endpoint of Cough Severity Visual 
Analogue Scale (VAS); severity was scored on a 100-mm VAS at Screening, Baseline, Days 28, 56, 84, 
85, 98, and 99. Other secondary endpoints included Daily Cough Score (DCS) and Cough Severity Diary 
where subjects provided scores from 0 [best] to 10 [worst] at Screening, Baseline, daily throughout the 
treatment period, and at Follow-Up. Subjects scored cough for DCS and scored 7 items with 3 subscales 
(cough frequency, intensity, and disruption) for CSD. Another secondary endpoint was Leicester Cough 
Questionnaire (LCQ), a measure of health-related quality of life13 completed at Baseline, and Days 28, 
56, and 85. Responder analyses on cough frequency reduction (i.e., ≥70% Reduction, ≥50% Reduction, 
and ≥30% Reduction) were also done as secondary endpoints.
Safety Evaluation
Vital signs, laboratory assessments and adverse events (AEs) were checked at each visit. AEs were 
assessed for their seriousness and relationship to study medication. Urinalysis and estimated glomerular 
filtration rate (eGFR) were performed at Screening and all treatment visits.  Paraesthesia/hypoaesthesia 
and dysgeusia were AEs of special interest and were queried further for frequency, severity, and duration 
using a structured taste questionnaire. An acceptability questionnaire administered at the end of treatment 
asked patients “How likely would you be to take this medication?” regarding the time frames of “twice 
daily”, “≥ 4 weeks”, “≥ 6 months”, or “≥ 1 year.”
Statistical Analyses
The primary hypothesis was that ≥one dose regimen of gefapixant was superior to placebo for the mean 
change from baseline in awake cough frequency (on the natural-log scale) at 12 weeks.  Assuming a 
dropout rate of 13%, approximately 200 patients were to be randomized (≥43 evaluable patients in each 
treatment group), providing 85% power to detect a difference of ≥25 coughs/hour for gefapixant vs. 
placebo for the primary endpoint. This assumed a standard deviation for the change from baseline of 38 
using a t-test (two-sided, significance level of 0.05). The sample size estimates were based on a previous 
study of gefapixant.9,10
The primary efficacy endpoint was analyzed using a mixed model repeated measures analysis and the 
baseline value (on the natural log scale) was included as a covariate. The treatment group means relative 
to placebo were compared at Day 84. Type I error rate for the primary efficacy testing was controlled by 
sequential comparisons of gefapixant vs. placebo from 50 mg to 20 mg and finally to 7·5 mg.
The Full Analysis Set (FAS; all randomized patients who have taken ≥1 dose of study medication 
and provided ≥1 baseline and ≥1 post baseline primary endpoint observation) was used to 
evaluate efficacy. The Per Protocol Set (PP; a subset of the FAS set who sufficiently complied 
with the protocol) was used to confirm efficacy parameters. The Safety Set (all randomized 
patients who have received ≥1 dose of study drug) was used to evaluate safety and tolerability. 
Role of the funding source
Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc., sponsored this study. Academic 
advisors and representatives of the sponsor participated in designing the study. Data collected by 
the investigators and their site personnel were analysed and interpreted by senior academic 
authors and representatives of the sponsor. All authors had full access to the data used to prepare 
this manuscript. The corresponding author wrote the first draft of the manuscript. All authors 
participated in critical review and editing, approved the submitted draft, vouch for the accuracy 




Of patients who were randomized, 76% were female, 92% white, and mean age was 60 years 
(Table 1). The mean duration of cough was 14·5 years. FEV1/FVC was normal (>80%) and the 
majority of patients had never smoked (70%). At baseline, the geometric mean (median) number 
of coughs/hour whilst awake was 27·6 (31·7), 27·4 (27·5), 24·1 (28·2), and 28·8 (28·0) for the 
placebo, 7·5-mg, 20-mg, and 50-mg groups, respectively. Mean cough severity VAS was 57·4, 
56·7, 58·3, and 57·9 mm for the placebo, 7·5-mg, 20-mg, and 50-mg groups, respectively. 
Of 367 screened patients, 253 were randomized; 236 were included in the FAS population, and 
252 patients were included in the Safety Set population. Out of 253 randomized patients, 222 
(88%) completed the study, with AEs reported as the most common reason for discontinuation 
(Figure 1).
Efficacy
Gefapixant 50 mg demonstrated a significant reduction in in awake cough frequency after 12 
weeks over placebo (primary endpoint); the percentage reduction over placebo was 37% (95%CI 
15 to 53%) (p=0·003), a reduction from baseline of 58% (95%CI 47 to 66%). The percentage 
reductions from baseline for the 7·5-mg and 20-mg doses [47% (95%CI 35 to 57%) and 48% 
(95%CI 35 to 58%) respectively] were greater than placebo [33% (95%CI 17 to 45%)], but the 
differences did not reach statistical significance (Table 2; Figure 2; Figure 3). At Week 14 (i.e., 2 
weeks after last dosing), the median change from Week 12 in awake cough frequency (c/hr) was 
3·0 (gefapixant 50 mg), 0·5 (gefapixant 20 mg), 1·4 (gefapixant 7·5 mg), and -1·0 (placebo) 
(Figure 3). Patients treated with gefapixant remained below baseline and thus did not exhibit 
evidence of a rebound effect.
A prespecified responder analysis evaluating levels of reduction in Awake Cough Frequency at 
Week 12 showed a numerically greater percentage of gefapixant 50-mg patients who experienced 
a ≥30% reduction vs. placebo [80% vs. 44%, p<0·001, a ≥50% reduction (51% vs. 25%, 
p=0·003) and a ≥70% reduction (31% vs. 16%, p=0·043)] (Supplemental Figure 1).
Secondary endpoint results supported the efficacy of gefapixant 50 mg and superiority over 
placebo; p-values for secondary efficacy variables are nominal (i.e., no adjustment for 
multiplicity). At 8 weeks, awake cough frequency and 24-hour cough frequency both improved 
over placebo with the 7·5-mg dose (p<0·05 and p<0·001) and awake cough frequency alone 
improved with the 20-mg dose (p<0·05) (Table 2). All doses of gefapixant demonstrated 
improvement in Cough VAS although the 50-mg dose demonstrated the most improvement 
versus placebo at each time point (Table 2; Figure 3). Daily measures of cough with DCS also 
demonstrated an improvement with gefapixant vs. placebo (Table 2). At Week 12, the mean 
reduction of gefapixant over placebo regarding mean daily cough severity diary (CSD) total 
score were 0·4, 0·6, and 0·7 for gefapixant 7·5 mg, 20 mg, and 50 mg, respectively (p= 0·02 for 
50 mg vs. placebo). Weekly improvements in CSD and DCS are illustrated in Figure 2 and 
Supplemental Figure 2. By Week 12, all doses of gefapixant demonstrated improvement in LCQ 
over placebo with the 50-mg dose demonstrating the most improvement over placebo (Table 2; 
Figure 3). 
Safety
The frequency of AEs, discontinuations due to AEs, and AEs determined to be related to 
treatment all increased in a dose-dependent manner (Table 3). Only one patient had a serious AE 
(frostbite); this occurred whilst taking gefapixant. Discontinuations were more frequent at the 
50-mg dose due to taste-related AEs such as ageusia (n=4), hypogeusia (n=2), and dysgeusia 
(n=2), as well as oral hypoaesthesia (n=2). 
Renal and urologic AEs were infrequent and not associated with study treatment. Taste-related 
AEs and oral paraesthesia/hypoaesthesia increased in frequency in a dose-dependent manner.  
Dysgeusia and hypogeusia, were the most common AEs in the study. Dysgeusia was reported in 
5%, 10%, 33%, and 48% of patients on placebo and gefapixant 7·5 mg, 20 mg, and 50 mg, 
respectively.
Benefit attributable to gefapixant was not limited to participants experiencing taste AEs; in a 
post-hoc analysis comparing patients who reported or did not report a taste-related AE, those not 
reporting taste-related AEs demonstrated improvements from pre-treatment baseline (with 95% 
CIs excluding 0), and qualitatively similar to improvements observed amongst participants who 
did experience taste AEs (Supplemental Figure 3). Of note, although 12% of patients receiving 
the 50-mg dose felt that their taste effects were extremely bothersome (0% in other dose groups), 
84% responding to the Acceptability Questionnaire stated that they were likely or extremely 
likely to take gefapixant for at least 1 year (Supplementary Table 1).
Discussion
This study is the first to demonstrate that P2X3 antagonism, or indeed any pharmacological 
intervention, has anti-tussive efficacy sustained over a 12-week period, evidenced by significant 
improvements in not only objective cough frequency but also patient reported outcomes with 
gefapixant 50 mg compared with placebo. In this study, which included RCC and UCC patients 
with characteristics typical for a chronic cough population, efficacy was apparent as early as 4 
weeks after initiation of treatment. At lower doses of gefapixant (20 mg and 7·5 mg), treatment 
effects were evident at earlier time points but did not reach statistical significance at 12 weeks 
compared with placebo. Gefapixant was generally well tolerated, dysgeusia being the most 
frequently reported adverse event.
The treatment of patients with RCC and UCC is a significant unmet clinical need as approved 
therapies are lacking. Consequently, patients suffer for many years from this condition with 
significant impacts on their quality of life;14-16 the typical duration of coughing in this study 
was 15 years. Single studies have provided some evidence that low dose morphine sulphate and 
gabapentin may improve cough specific quality of life over shorter time periods, however both 
therapies are associated with significant side effects and neither study evaluated treatment effects 
objectively using 24-hour cough frequency.4,5 Nonetheless, the improvements in patient-
reported outcomes with gefapixant in this study compare very favourably with those previously 
reported for these unapproved therapies.
In this study, gefapixant was generally well tolerated, with only one serious adverse event, 
deemed unrelated to the study drug. Taste disturbances with gefapixant were commonly reported 
and exhibited a clear dose relationship. Gefapixant is a first-in-class, non-competitive inhibitor of 
the P2X3 ion channel, with some selectivity for this homomeric channel over heteromeric 
P2X2/3 channels. In addition to evidence that P2X3 receptors are expressed by airway sensory 
nerves activating cough, both P2X3 and P2X2/3 receptors have been described on fibres 
innervating taste buds.17 In rodents, heteromeric P2X2/3 channels are thought to play a central 
role in mediating taste, which could explain the adverse taste events associated with this therapy. 
However, the role of P2X3 versus P2X2/3 receptors in mediating taste in humans is not well 
understood, and it is feasible that in humans, taste alterations associated with gefapixant are 
largely mediated by inhibition at P2X3 receptors. Of note, in the current study few patients 
discontinued therapy as a consequence of taste adverse experiences, and most patients stated that 
they would continue treatment for at least a year. 
This large-scale multi-centre cough monitoring study both corroborates and extends previous 
data supporting the efficacy of gefapixant in RCC and UCC, including an initial proof-of-concept 
study for the anti-tussive effects of P2X3 antagonism8 and investigation of the balance between 
efficacy and tolerability at lower doses.9,10 In previous studies, improvements in cough 
frequency and patient reported outcomes were demonstrated for much shorter treatment periods 
of 4 days to 14 days, and for doses as low as 15 mg BID. The reductions in cough frequency 
observed in this study for the 20-mg and 7·5-mg doses of gefapixant did not reach statistical 
significance as the magnitude of the placebo effect was larger than that previously observed.
It is interesting that in most previous studies testing anti-tussive agents in RCC and UCC, 
placebo effects were not reported, whereas in this study we observed a significant placebo effect 
influencing all the endpoints evaluated, including objective cough frequency. Direct comparisons 
with previous trials are difficult as large-scale multi-centre parallel group studies have rarely 
been undertaken and none have used 24-hour objective cough monitoring as an endpoint. 
Smaller proof-of-concept studies in chronic cough generally employed crossover designs and 
have reported little change in patients treated with placebo. Knowledge of the these successful 
gefapixant studies, and the greater likelihood (75%) of assignment to a gefapixant group, may 
have substantially changed expectations for patients participating in this particular trial, 
contributing to the placebo effect observed.
In conclusion, targeting P2X3 channels with gefapixant at a dose of 50 mg BID was generally 
well tolerated and significantly reduced the frequency of cough in patients with RCC and UCC 
after 12 weeks compared with placebo. Gefapixant therefore shows promise as a novel therapy 
for chronic cough and further studies examining longer-term anti-tussive benefit are warranted.
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   Female 47 (75%) 48 (75%) 48 (76%) 50 (79%) 193 (76%)
Age
   Mean (SD) 60·0 (10·90) 59·9 (10·46) 61·8 (9·13) 59·3 (9·19) 60·2 (9·94)
   Min, Max 23, 76 22, 78 40, 79 36, 77 22, 79
Race
White 59 (94%) 60 (94%) 60 (95%) 55 (87%) 234 (92%)
Other* 4 (6%) 4 (6%) 3 (5%) 8 (13%) 19 (8%)
Mean (SD) 









17·1 (13·32) 13·5 (10·00) 14·9 (13·94) 12·3 (8·19) 14·5 (11·67)
Country
   USA 42 (67%) 41 (64%) 41 (65%) 41 (65%) 165 (65%)
   UK 21 (33%) 23 (36%) 22 (35%) 22 (35%) 88 (35%)
Smoking 
Status
Never 45 (71%) 49 (77%) 35 (56%) 48 (76%) 177 (70%)
Former 
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57·4 (23·1) 56·7 (20·7) 58·3 (25·1) 57·9 (19·7) 57·6 (22·2)
* Includes Black/African American, American Indian or Alaska Native, Asian, Native Hawaiian or Other Pacific 
Islander, or Multiple.
















Baseline 27·6 27·4 24·1 28·8
Week 4 17·7 14·2 14·4 11·8‡








to Placebo (95% 
CI)






hr Cough Frequency 
(c/h)
Baseline 20·5 20·0 17·6 21·9
Week 4 13·1 10·5 10·8 8·7‡
Week 8 14·5 9·2† 9·5 7·9‡




to Placebo (95% 
CI)







Cough Severity VAS 
(mm)
Baseline Mean 
(SD) 57·4 (23·13) 56·7 (20·65) 58·3 (25·12) 57·9 (19·72)
Week 12 LS 
Mean (95% CI) 
Change from 
Baseline 
-16·7 (-22·7, -10·7) -21·1 (-27·2, -15·1) -23·1 (-29·1, -17·0) -27·9 (-34·1, -21·6) †
CSD Total Score
Baseline Mean 
(SD) 4·1 (1·82) 4·1 (1·65) 4·2 (2·10) 4·3 (1·80)
Week 12 LS 
Mean (95% CI)) 
Change from 
Baseline







(SD) 5·4 (1·81) 5·2 (1·74) 5·5 (1·94) 5·3 (1·72)
Week 12 Mean 
(SD) Change 
from Baseline
-1·5 (1·83) -1·9 (2·00) -2·3 (2·32) -2·1 (1·86)
Total LCQ Score
Baseline Mean 
(SD) 12·2 (2·81) 12·1 (2·66) 12·0 (3·30) 11·4 (2·82)
Week 12 LS 
Mean (95% CI) 
Change from 
Baseline
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Week 4 13·1 10·5 10·8 8·7‡
Week 8 14·5 9·2† 9·5 7·9‡
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Cough Severity VAS 
(mm)
Baseline Mean 
(SD) 57·4 (23·13) 56·7 (20·65) 58·3 (25·12) 57·9 (19·72)
Week 12 LS 
Mean (95% CI) 
Change from 
Baseline 
-16·7 (-22·7, -10·7) -21·1 (-27·2, -15·1) -23·1 (-29·1, -17·0) -27·9 (-34·1, -21·6) †
CSD Total Score
Baseline Mean 
(SD) 4·1 (1·82) 4·1 (1·65) 4·2 (2·10) 4·3 (1·80)
Week 12 LS 
Mean (95% CI)) 
Change from 
Baseline







(SD) 5·4 (1·81) 5·2 (1·74) 5·5 (1·94) 5·3 (1·72)
Week 12 Mean 
(SD) Change 
from Baseline
-1·5 (1·83) -1·9 (2·00) -2·3 (2·32) -2·1 (1·86)
Total LCQ Score
Baseline Mean 
(SD) 12·2 (2·81) 12·1 (2·66) 12·0 (3·30) 11·4 (2·82)
Week 12 LS 
Mean (95% CI) 
Change from 
Baseline
2·1 (1·3, 3·0) 3·3 (2·4, 4·2) 3·2 (2·3, 4·0) 4·0 (3·1, 4·9) †
FAS Population.
†p<0·05; ‡p<0·001. 
*Mixed model repeated measures analysis (change from baseline used as the dependent variable, and includes the 
treatment group, visit, country, the interaction between treatment and visit as fixed factors, and baseline as a 
covariate).















Any AE 39 (61·9%) 44 (69·8%) 54 (85·7%) 58 (92·1%) 156 (82·5%)
Discontinued 
due to AE 2 (3·2%) 2 (3·2%) 3 (4·8%) 10 (15·9%) 15 (7·9%)
Serious AE 0 0 0 1 (1·6%) 1 (0·5%)
AEs Related 

















8 (12·7%) 6 (9·5%) 7 (11·1%) 13 (20·6%) 26 (13·8%)
Most 
Common AEs
Dysgeusia 3 (4·8%) 6 (9·5%) 21 (33·3%) 30 (47·6%) 57 (30·2%)
Hypogeusia 1 (1·6%) 0 11 (17·5%) 15 (23·8%) 26 (13·8%)





2 (3·2%) 5 (7·9%) 9 (14·3%) 6 (9·5%) 20 (10·6%)
Ageusia 1 (1·6%) 0 3 (4·8%) 13 (20·6%) 16 (8·5%)
Paraesthesia 
Oral 5 (7·9%) 4 (6·3%) 5 (7·9%) 4 (6·3%) 13 (6·9%)
Cough 2 (3·2%) 2 (3·2%) 5 (7·9%) 5 (7·9%) 12 (6·3%)
Hypoaesthe
sia Oral 3 (4·8%) 2 (3·2%) 4 (6·3%) 5 (7·9%) 11 (5·8%)
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Common AEs
Dysgeusia 3 (4·8%) 6 (9·5%) 21 (33·3%) 30 (47·6%) 57 (30·2%)
Hypogeusia 1 (1·6%) 0 11 (17·5%) 15 (23·8%) 26 (13·8%)





2 (3·2%) 5 (7·9%) 9 (14·3%) 6 (9·5%) 20 (10·6%)
Ageusia 1 (1·6%) 0 3 (4·8%) 13 (20·6%) 16 (8·5%)
Paraesthesia 
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2 (3·2%) 3 (4·8%) 5 (7·9%) 2 (3·2%) 10 (5·3%)
* AEs determined by the investigator to be possible, probably, or definitely related to study 
treatment.
** Taste-related AEs include dysgeusia, hypogeusia, and ageusia.
Figure 1: CONSORT Diagram showing patient disposition throughout the study. *FAS 
Population is the Full Analysis Set, which included all randomized patients who had taken at 
least 1 dose of study medication and provided at least 1 baseline and at least 1 post baseline 
primary endpoint observation during the treatment period. †Safety Set is defined as all patients 
who were randomized and received any amount of study treatment.
 
Figure 2: % Difference (95% CI) from Placebo for Awake Cough Frequency. Evaluated using a 
mixed effect repeated measures (MMRM) model that includes fixed effects for treatment group, 
visit, country, the treatment-by-visit interaction, and the baseline value as a covariate. The 
analysis of Awake Cough Frequency and 24-hour Cough Frequency was based on log-
transformed data. FAS Population. 
Figure 3: Efficacy Measurements over Time
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Full Inclusion and Exclusion Criteria
Patients who meet all of the following criteria were included in the study:
1. Women and men between 18 and 80 years of age inclusive
2. Chest radiograph or CT thorax within the last 5 years not demonstrating any abnormality considered to be 
significantly contributing to the chronic cough in the opinion of the PI and Sponsor medical monitor
3. Had a diagnosis of refractory chronic cough or unexplained cough for at least 1 year (see American College of 
Chest Physicians/British Thoracic Society (ACCP/BTS) guidelines)
4. Had a score of ≥40 mm on the Cough Severity VAS at Screening
5. Women of child-bearing potential must have used 2 forms of acceptable birth control method from Screening 
through the Follow-Up Visit. Acceptable birth control methods included: established use of oral, injected, or 
implanted hormonal methods of contraception; intrauterine device (IUD) or intrauterine system (IUS); tubal ligation; 
or male sterilization. Double-barrier method (diaphragm for female patient and condom for male partner with 
spermicidal) satisfied the requirement for 2 forms of acceptable birth control. When in line with the preferred life 
style of the patient, true and complete abstinence (not periodic abstinence) was acceptable
6. Male patients and their partners of child-bearing potential must have used 2 methods of acceptable birth control, 1 
of which must have been a barrier method, and have agreed to make no donation of sperm from Screening until 3 
months after the last dose of study treatment
7. Provided written informed consent
8. Were willing and able to comply with all aspects of the protocol.
Patients were NOT eligible for this study if they met any of the following criteria:
1. Current (at the time of study entry) smoker
2. Individuals who had given up smoking within the past 6 months prior to study entry
3. Initiation of treatment with an angiotensin converting enzyme (ACE)-inhibitor within 4 weeks prior to the 
Baseline Visit (Day 0) or during the study
4. Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) < 60%
5. History of upper or lower respiratory tract infection or recent significant change in pulmonary status within 4 
weeks of the Baseline Visit (Day 0)
6. History of cystic fibrosis or bronchiectasis
7. History of opioid use within 1 week of the Baseline Visit (Day 0)
8. Requiring concomitant therapy with prohibited medications (see Section 6.6 of the protocol [16.1.1.4])
9. Body mass index (BMI) <18 kg/m2 or ≥40 kg/m2
10. History or symptoms of renal disease or renal obstructive disease
11. History of triple phosphate kidney/bladder stones (nephro-/uro-lithiasis)
12. History of conditions or disorders that predisposed to nephrolithiasis such as inflammatory bowel disease (i.e., 
Crohn’s disease and active ulcerative colitis), or short bowel syndrome
13. Estimated glomerular filtration rate (eGFR) <60 mL/min/1·73 m2 (using the Chronic Kidney Disease 
Epidemiology Collaboration (CKD EPI) formula [http://mdrd.com/]) at Screening
14. History of concurrent malignancy or recurrence of malignancy within 2 years prior to Screening (not including 
patients with <3 excised basal cell carcinomas)
15. History of a diagnosis of drug or alcohol dependency or abuse within approximately the last 3 years prior to 
study entry
16. Any condition possibly affecting drug absorption (e.g., gastrectomy, gastroplasty, any type of bariatric surgery, 
or vagotomy)
17. Screening systolic blood pressure (SBP) >160 mm Hg or a diastolic blood pressure (DBP) >90 mm Hg;
18. Clinically significant abnormal electrocardiogram (ECG) at Screening, including any of the following:
- Corrected QT interval (QTc) interval >450 milliseconds in males and >470 milliseconds in females,
- Atrial fibrillation or atrial flutter
- Heart rate <40 beats per minute (BPM) or >110 bpm
19. Personal or family history of congenital long QT syndrome or family history of sudden death
20. Significantly abnormal laboratory tests at Screening, including:
- alkaline phosphatase (AP), alanine aminotransferase (ALT, serum glutamic pyruvic transaminase [SGPT]), 
aspartate aminotransferase (AST, serum glutamic oxaloacetic transaminase [SGOT]), or bilirubin >150% of the 
upper limit of normal (ULN)
- haemoglobin < 10 gm/dL, white blood cell (WBC) count <2500 mm3, neutrophil count <1500 mm3, platelet count 
<100 × 103/mm3
- positive tests for drugs of abuse
- Positive tests at Screening for viral hepatitis defined by positive immunoglobulin M(IgM) anti-hepatitis A virus 
(HAV), hepatitis B virus (HepB) surface antigen, or antihepatitis C virus (HCV), human immunodeficiency virus 
(HIV) 
21. History of cutaneous adverse drug reaction to sulphonamides or signs and symptoms suggestive of anaphylaxis 
to sulphonamides
22. Pregnant or breastfeeding at the time of Screening
23. Treatment with an investigational drug (except gefapixant) or investigational biologic within 60 days preceding 
the first dose of study treatment or plans to take another investigational drug or biologic within 30 days of study 
completion
24. Blood donation within 56 days or plasma donation within 7 days prior to dosing
25. Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the 
risk associated with study participation or investigational product administration or may interfere with the 
interpretation of study results and, in the judgment of the Investigator or Sponsor, would make the patient 
inappropriate for entry into this study.
Figure S1: Prespecified Responder Analysis of Awake Cough Frequency at Week 12
Figure S2: Daily Cough Assessments
Mean total DCS over 12 Weeks
Figure S3: Model-Estimated Mean Change from Baseline in Awake Cough Frequency and 
95% Confidence Interval in Gefapixant Treatment Groups - Full Analysis Set. *The Mixed 
Model Repeated Measures analysis used log transformed Awake Cough Frequency as the response variable and 
included treatment, visit, country, and treatment-by-visit interaction as well as log-transformed baseline ACF as 
covariate. It should be noted that the “Yes” group for gefapixant 7·5 mg were small and results should be viewed 
with caution (i.e., n=4 at Day 28; n=0 at Day 56; n=2 at Day 84).












How likely would you be 
to take this Medication?
For at least one year
N 60 58 58 57
Extremely unlikely 2 (3·3%) 4 (6·9%) 3 (5·2%) 1 (1·8%)
Unlikely 2 (3·3%) 1 (1·7%) 2 (3·4%) 7 (12·3%)
Neither likely or unlikely 3 (5·0%) 3 (5·2%) 7 (12·1%) 1 (1·8%)
Likely 18 (30·0%) 9 (15·5%) 8 (13·8%) 17 (29·8%)
Extremely likely 35 (58·3%) 41 (70·7%) 38 (65·5%) 31 (54·4%)
p-value (AF-219 vs 
Placebo) 0·8464 0·7687 0·4364
For at least 6 months
N 60 57 58 57
Extremely unlikely 2 (3·3%) 3 (5·3%) 3 (5·2%) 1 (1·8%)
Unlikely 1 (1·7%) 2 (3·5%) 2 (3·4%) 6 (10·5%)
Neither likely or unlikely 4 (6·7%) 2 (3·5%) 4 (6·9%) 2 (3·5%)
Likely 13 (21·7%) 8 (14·0%) 10 (17·2%) 17 (29·8%)
Extremely likely 40 (66·7%) 42 (73·7%) 39 (67·2%) 31 (54·4%)
p-value (AF-219 vs 
Placebo) 0·9966 0·6372 0·2155
For at least 4 weeks
N 60 58 58 57
Extremely unlikely 2 (3·3%) 3 (5·2%) 3 (5·2%) 0
Unlikely 1 (1·7%) 1 (1·7%) 1 (1·7%) 3 (5·3%)
Neither likely or unlikely 2 (3·3%) 1 (1·7%) 4 (6·9%) 5 (8·8%)
Likely 11 (18·3%) 11 (19·0%) 9 (15·5%) 15 (26.3%)
Extremely likely 44 (73·3%) 42 (72·4%) 41 (70·7%) 34 (59·6%)
p-value (AF-219 vs 
Placebo) 0·7559 0·5091 0·2790
Twice daily
N 60 57 57 56
Extremely unlikely 2 (3·3%) 4 (7·0%) 3 (5·3%) 1 (1·8%)
Unlikely 0 0 2 (3·5%) 3 (5·4%)
Neither likely or unlikely 2 (3·3%) 3 (5·3%) 2 (3·5%) 5 (8·9%)
Likely 12 (20·0%) 9 (15·8%) 13 (22·8%) 17 (30·4%)
Extremely likely 44 (73·3%) 41 (71·9%) 37 (64·9%) 30 (53·6%)
p-value (AF-219 vs 
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For at least 6 months
N 60 57 58 57
Extremely unlikely 2 (3·3%) 3 (5·3%) 3 (5·2%) 1 (1·8%)
Unlikely 1 (1·7%) 2 (3·5%) 2 (3·4%) 6 (10·5%)
Neither likely or unlikely 4 (6·7%) 2 (3·5%) 4 (6·9%) 2 (3·5%)
Likely 13 (21·7%) 8 (14·0%) 10 (17·2%) 17 (29·8%)
Extremely likely 40 (66·7%) 42 (73·7%) 39 (67·2%) 31 (54·4%)
p-value (AF-219 vs 
Placebo) 0·9966 0·6372 0·2155
For at least 4 weeks
N 60 58 58 57
Extremely unlikely 2 (3·3%) 3 (5·2%) 3 (5·2%) 0
Unlikely 1 (1·7%) 1 (1·7%) 1 (1·7%) 3 (5·3%)
Neither likely or unlikely 2 (3·3%) 1 (1·7%) 4 (6·9%) 5 (8·8%)
Likely 11 (18·3%) 11 (19·0%) 9 (15·5%) 15 (26.3%)
Extremely likely 44 (73·3%) 42 (72·4%) 41 (70·7%) 34 (59·6%)
p-value (AF-219 vs 
Placebo) 0·7559 0·5091 0·2790
Twice daily
N 60 57 57 56
Extremely unlikely 2 (3·3%) 4 (7·0%) 3 (5·3%) 1 (1·8%)
Unlikely 0 0 2 (3·5%) 3 (5·4%)
Neither likely or unlikely 2 (3·3%) 3 (5·3%) 2 (3·5%) 5 (8·9%)
Likely 12 (20·0%) 9 (15·8%) 13 (22·8%) 17 (30·4%)
Extremely likely 44 (73·3%) 41 (71·9%) 37 (64·9%) 30 (53·6%)
p-value (AF-219 vs 
Placebo) 0·3887 0·2333 0·0534
p-value using stratified Cochran Mantel Haenszel (CMH) Test (stratified by country).
